Neuroperformance Evaluation of Multiple Sclerosis Disease Progression in a Clinical Trial: Implications for Neurological Outcomes

1. Slater RJ . Scoring techniques and problems in the evaluation of change in patients. Arch Neurol1983;40:675–77.

2. Willoughby EW , Paty DW . Scales for rating impairment in multiple sclerosis: a critique. Neurol1988;38:1793–98.

3. LaRocca NG , Scheinberg LC , Slater RJ . Field testing of a minimal record of disability in multiple sclerosis: the United States and Canada. Acta Neurol Scand1984;70:126–38.

4. Kurtzke JF . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurol1983;33:1444–52.

5. Noseworthy JH , Vandervoort MK , Wong CJ , Ebers GC , Group CCMS . Interrater variability with the expanded disability status scale (EDSS) and functional systems (FS) in a multiple sclerosis clinical trial. Neurol1990;40:971–75.

6. LaRocca NG . Statistical and methodological considerations in scale development. Boston: Butterworth, 1989.

7. Belendiuk G , Klatzman D , Mietlowski W , The M.S. Study Group . Rating scales in assessment of multiple sclerosis. In: Davis R , Kondraske GV , Tourtellotte WW , Syndulko K (eds.). Quantifying neurologic performance. Philadelphia: Hanley & Belfus, Inc., 1989:177–84.

8. Hauser SL , Dawsen DM , Lehrich JR , et al. Intensive immunosuppression in progressive multiple sclerosis. N Engl J Med1983;308:173–80.

9. Mickey MR , Ellison GW , Myers LW . An illness severity score for multiple sclerosis. Neurol1984;34:1343–47.

10. Sipe JC , Knobler RL , Braheny SL , et al. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurol1984;34:1368–72.

11. Nuwer MR , Packwood JW , Myers LW , Ellison GW . Evoked potentials predict the clinical changes in a multiple sclerosis drug study. Neurol1987;37:1754–61.

12. Huber M , Bamborschke S , Assheuer J , Heiss WD . Intravenous natural beta interferon treatment of chronic exacerbating-remitting multiple sclerosis: clinical response and MRI/CSF findings. J Neurol1988;235:171–73.

13. Kappos L , Städt D , Keil W , et al. A six-month magnetic resonsance imaging (MRI) follow-up study comparing the effects of cyclosporine A (Cs) and azathioprine (Aza) in the treatment of multiple sclerosis (MS). Neurol1987;37:231.

14. Myers LW , Ellison GW . Serial magnetic resonance imaging scans in multiple sclerosis. Ann Neurol1990;28:277.

15. Tourtellotte WW , Syndulko K , Baumhefner RW , Potvin AR . Neuroimmunologic pharmacology of multiple sclerosis. I. A comprehensive protocol for preliminary clinical trials in MS. Suffolk: Stuart Phillips Publ., 1986.

16. Baumhefner RW , Mendez M , Ma B , Tourtellotte WW . Modulation of de novo central nervous system IgG synthesis with preservation of oligoclonal IgG in multiple sclerosis. Neurol1979;29:552.

17. Baumhefner RW , Tourtellotte WW , Syndulko K , Shapshak P . Neuroimmunologic pharmacology of multiple sclerosis. II. Evaluation of immunosuppressive agents. In: Hommes OR , Mertin J , Tourtellotte WW (eds.). Immunotherapies in multiple sclerosis. Suffolk: Stuart Phillips Publ., 1986:226–36.

18. Tourtellotte WW , Haerer AF , Simpson JF , et al. Quantitative clinical neurological testing. I. A study of a battery of tests designed to evaluate in part the neurologic function of patients with multiple sclerosis and its use in a therapeutic trial. Ann NY Acad Sci1965;122:480–505.

19. Potvin AR , Tourtellotte WW . Quantitative examination of neurologic function. Boca Raton: CRC Press, Inc., 1985.

20. Tourtellotte WW , Syndulko K . Two decades of experience using quantitative examination of neurologic functions. In: Davis R , Kondraske GV , Tourtellotte WW , Syndulko K (eds.). Quantifying performance in neurology, physical medicine and rehabilitation: state of the art reviews. Philadelphia: Hanley & Belfus, Inc., 1989:161–67.

21. Tourtellotte WW , Syndulko K . Quantifying the neurologic examination: principles, constraints and opportunities. In: Munsat TL (ed.). Quantification of neurologic deficit. Stoneham, MA: Butterworth, 1989:(Chapter 2)7–16.

22. Kondraske GV . Neuromuscular performance resource economics and product-based composite indices. IEEE Engineering in Medicine & Biology Society. 11th Annual International Conference. 1989

23. Kondraske GV , Smith SS , Mooney V , et al. Computerized measurement of human function performance. In: Davis R , Kondraske GV , Tourtellotte WW , Syndulko K (eds.). Quantifying neurologic performance. Philadelphia: Hanley & Belfus, Inc., 1989:9–30.

24. Syndulko K , Tourtellotte WW . What is neurologically normal? In: Munsat TL (ed.). Quantification of neurologic deficit. Boston: Butterworth, 1989:17–31.

25. Rose AS , Kuzma JW , Kurtzke JF , et al. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs placebo. Final Report. Neurology1970;20:1–59.

26. Dixon WJ , Kuzma JW . Data reduction in large clinical trials. Comm Stat1974;3:301–24.

27. Henderson WB , Tourtellotte WW , Potvin AR , Rose AS . Methodology for analyzing clinical neurological data: ACTH in multiple sclerosis. Clin Pharmacol Ther1978;24:146–53.

28. The Multiple Sclerosis Study Group. Efficacy and toxicity of Cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol1990;27:591–605.

29. McFarland HF . Multiple Scerosis. In: Porter RJ , Schoenberg BS (eds.). Controlled clinical trials in neurological disease. Boston: Kluwer Academic Publishers, 1990:321–41.

30. Smith A. Symbol Digit Modalities Test. Manual. Los Angeles: Western Psychological Services, 1973.

31. Baumhefner RW , Tourtellotte WW , Syndulko K , et al. Quantitative multiple sclerosis plaque assessment with magnetic resonance imaging. Its correlation with clinical parameters, evoked potentials and intra-blood-brain-barrier IgG synthesis. Arch Neurol1990;47:19–26.

32. Potvin AR , Syndulko K , Tourtellotte WW , Lemmon JA , Potvin JH . Human neurological function and the normal aging process. J Am Geriat Soc1980;28:1–9.

33. Potvin AR , Syndulko K. Tourtellotte WW , et al. Quantitative evaluation of normal age-related changes in neurologic function. In: Malleta GJ , Pirozzolo FJ (eds.). Behavioral assessment and psychopharmacology. Advances in Neurogerontology. New York: Praeger, 1981:13–57.

34. Winer BJ . Statistical principles in experimental design. New York: McGraw-Hill, 1971.

35. Behbehani K , Kondraske GV , Richmond JR . Investigation of upper extremity visuomotor control performance measures. IEEE Trans Biomed Engin1988;35:518–25.

36. Tourtellotte WW , Baumhefner RW , Shapshak P . Measuring intra-BBB IgG synthesis rate by formula in multiple sclerosis. J Neuroimmunol1988;17:262.

37. Staugaitis SM , Shapshak P , Tourtellotte WW , Lee MM , Reiber HO . Isoelectric focusing of unconcentrated cerebrospinal fluid: application to ultrasensitive analysis of oligoclonal immunoglobulin-G. Electrophoresis.1985;6:287–91.

38. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates, Publishers, 1988.

39. Franklin GM , Heaton RK , Nelson LM , Filley CM , Seibert C . Correlation of neuropsychological and MRI findings in chronic/progressive multiple sclerosis. Neurol1988;38:1826–29.

40. Rao SM , Leo GJ , Haughton VM , St. Aubin-Faubert P , Bernardin L. Correlation of magnetic resonance imaging with neuropsychological testing in multipleSclerosis.1989;39:161–66.

41. Kappos L , Pfeuffer B , Staedt D , et al. Quantitative magnetic resonance imaging of the multiple sclerosis brain: localization rather than total volume of lesions correlates with cerebrospinal fluid IgG level and visual evoked response abnormalities. Ann Neurol1988;24:169.

42. Huber SJ , Paulson GW , Shuttleworth EC , et al. Magnetic resonance imaging correlates of dementia in multiple sclerosis. Arch Neurol1987;44:732–36.

43. Baumhefner RW , Syndulko K , Tourtellotte WW , et al. Multiple sclerosis: area and circumference correlations of MRI-demonstrated lesions with CSF parameters and measurements of clinical disability. Neurol1991;41 (Suppl 1):144.

44. Rao SM , Leo GJ , Bernardin L , Unverzagt F . Cognitive dysfunction in multiple sclerosis: I. Frequency, patterns, and prediction. Neurol1991;41:685–91.

45. Kurtzke JF . 1. Clinical considerations. In: Porter RJ , Schoenberg BS (eds.). Controlled clinical trials in neurological disease. Boston: Kluwer Academic Publishers, 1990:3–16.

46. Kondraske GV . A PC-based performance measurement laboratory system. J Clin Engr1990;15:467–78.

47. Munsat TL , Andres PL , Skerry LM . The use of quantitative techniques to define amyotrophic lateral sclerosis. In: Munsat TL (ed.). Quantification of neurologic deficit. Boston: Butterworth, 1989:129–42.

48. Munsat TL , Andres PL , Skerry LM . Quantitative assessment of deficit in amyotrophic lateral sclerosis. In: Davis R , Kondraske GV , Tourtellotte WW , Syndulko K (eds.). Quantifying neurologic performance. Philadelphia: Hanley & Belfus, Inc., 1989:188–93.

49. Williams JI, Wood-Dauphinee S. Assessing quality of life. 1990.

50. Ottenbacher KJ , Barrett KA . Measures of effect size in the reporting of rehabilitation research. Am J Phys Med Rehabil1991;70 (Suppl. 1):S131–S137.

51. Paty DW , Oger JJF , Kastrukoff LF , et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurol1988;38:180–85.

52. Poser CM , Paty DW , Scheinberg L , et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol1983;13:227–31.